CD274 and non-small cell lung carcinoma: The therapeutic landscape in metastatic NSCLC changed with the approval of immunotherapy agents, particularly immune checkpoint inhibitors (ICIs), targeting the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway for both treatment-näive and previously treated disease, irrespective of histology.